EUVIMEDEUVIMED entdecken
Crossref

Somatostatin receptor activity assessed by 68Ga-DOTATOC PET can preoperatively predict DAXX/ATRX loss of expression in well-differentiated pancreatic neuroendocrine tumors

Paola Mapelli, Carolina Bezzi, Francesca Muffatti, Samuele Ghezzo, Francesco Baldassi, Marco Schiavo Lena, Valentina Andreasi, Carla Canevari, Patrizia Magnani, Francesco De Cobelli, Luigi Gianolli, Stefano Partelli und 2 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2023

DOI: 10.1007/s00259-023-06210-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2023. Verfasst von Paola Mapelli und 13 weiteren Autor:innen. Beteiligte Einrichtung: Vita-Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate the role of 68Ga-DOTATOC PET parameters in predicting DAXX/ATRX loss of expression in patients with Pancreatic neuroendocrine tumors (PanNET) candidate to surgery. METHODS: This retrospective study included 72 consecutive patients with PanNET (January 2018-March 2022) who underwent to 68Ga-DOTATOC PET for preoperative staging. Image analysis: qualitative assessment and extraction of SUVmax, SUV mean, somatostatin receptor density (SRD), and total lesion somatostatin receptor density (TLSRD) from primary PanNET. Radiological diameter and biopsy information (grade, Ki67) were collected. Loss of expression (LoE) of DAXX/ATRX was assessed by immunohistochemistry on surgical specimen. Student t-test, univariate and multivariate logistic regression and ROC curves have been used to investigate the predictive value of PET parameters on DAXX/ATRX LoE. RESULTS: Forty-two/72 patients had a G1, 28/72 a G2, and 2/72 a G3 PanNET. Seven/72 patients had DAXX LoE, 10/72 ATRX LoE, and 2/72 DAXX/ATRX LoE. SRD and TLSRD could predict DAXX LoE (p = 0.002, p = 0.018, respectively). By evaluating SRD in combination with radiological diameter, only SRD maintained statistical significance (multivariate logistic regression: p = 0.020, OR = 1.05), providing the best prediction (AUC-ROC = 79.01%; cut-off = 46.96; sensitivity = 77.78%; specificity = 88.89%). In the sub-analysis performed on 55 patients with biopsy availability, SRD demonstrated its role in providing useful and additional information (multivariate logistic regression: SRD p = 0.007; grade p = 0.040). CONCLUSION: SRD has a predictive role on DAXX LoE in PanNETs, with higher probability of LoE at increasing SRD values. SRD provides complementary/additional information to grade assessed on biopsy material, and the combined use of these approaches might support patients' management by preoperatively identifying subjects with more aggressive diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPancreatic NeoplasmsHumansX-linked Nuclear ProteinReceptors, SomatostatinGallium RadioisotopesRetrospective StudiesAdaptor Proteins, Signal TransducingPositron-Emission TomographyMolecular ChaperonesCo-Repressor ProteinsOctreotide

Stichwörter der Autor:innen

68Ga-DOTA-peptidesATRXDAXXPETPancreatic neuroendocrine tumorPredictive valuePreoperativeRisk assessmentSomatostatin receptor activity

Substanzen

X-linked Nuclear ProteinReceptors, SomatostatinGallium RadioisotopesAdaptor Proteins, Signal TransducingMolecular ChaperonesCo-Repressor ProteinsEdotreotideOctreotideATRX protein, humanDAXX protein, human

Autor:innen und Institutionen

  • Vita-Salute San Raffaele University, Milan, Italy.
  • Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Pancreatic Surgery Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • University of Milano-Bicocca, Milan, Italy.
  • Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Zitieren

APA

Mapelli, P., Bezzi, C., Muffatti, F., Ghezzo, S., Baldassi, F., Schiavo Lena, M., Andreasi, V., Canevari, C., Magnani, P., De Cobelli, F., Gianolli, L., Partelli, S., Falconi, M., & Picchio, M. (2023). Somatostatin receptor activity assessed by 68Ga-DOTATOC PET can preoperatively predict DAXX/ATRX loss of expression in well-differentiated pancreatic neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-023-06210-7

Vancouver

Mapelli P, Bezzi C, Muffatti F, Ghezzo S, Baldassi F, Schiavo Lena M, et al. Somatostatin receptor activity assessed by 68Ga-DOTATOC PET can preoperatively predict DAXX/ATRX loss of expression in well-differentiated pancreatic neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging. 2023. doi:10.1007/s00259-023-06210-7

BibTeX
@article{Mapelli2023,
  author = {Mapelli, Paola and Bezzi, Carolina and Muffatti, Francesca and Ghezzo, Samuele and Baldassi, Francesco and Schiavo Lena, Marco and Andreasi, Valentina and Canevari, Carla and Magnani, Patrizia and De Cobelli, Francesco and Gianolli, Luigi and Partelli, Stefano and Falconi, Massimo and Picchio, Maria},
  title = {Somatostatin receptor activity assessed by 68Ga-DOTATOC PET can preoperatively predict DAXX/ATRX loss of expression in well-differentiated pancreatic neuroendocrine tumors},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2023},
  doi = {10.1007/s00259-023-06210-7}
}
Kostenlos starten →